Keywords: Hepatitis C, EASL, Boehringer Ingelheim, Novartis, Bristol-Myers Squibb, Alisporivir

EASL meeting hears impressive data on hep C candidates from Boehringer, Novartis and Bristol-Myers

Article | 04 April 2011

Print This

There was a batch of good news coming out of the 46th annual meeting of the European Association for the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in